The Serotonin Myth: Why the Medicalization of Emotion is Failing Us

The chemical imbalance theory of depression, a narrative that has dominated mental health for decades, is not a scientific fact but a marketing construct. Research by Dr. Joanna Moncrieff reveals that this framework pathologizes normal human emotional responses while justifying long-term reliance on pharmaceutical drugs. By shifting the focus from finding root causes to suppressing symptoms, this model creates a cycle of dependency that hides the impact of social, nutritional, and environmental stressors. For patients and practitioners, the advantage lies in rejecting the broken brain narrative in favor of a holistic, individualized approach that restores personal agency. Understanding this systemic shift is necessary for anyone seeking to move beyond superficial symptom management toward genuine recovery.

The Illusion of Targeted Treatment

The serotonin theory of depression began in the 1960s as a theoretical hypothesis, not an established clinical reality. By the 1980s, the theory was largely in decline due to a lack of supporting evidence. However, the pharmaceutical industry revived the concept to market Selective Serotonin Reuptake Inhibitors (SSRIs), needing a way to distinguish these new drugs from the stigmatized, dependency-prone benzodiazepines of the previous era.

"The industry wanted to persuade people that these drugs were different from the old benzodiazepines, they weren't just numbing you or tranquilizing you. They were doing something really important. They were targeting you had an abnormality in your brain and they would have done a target that and put it right."

-- Dr. Joanna Moncrieff

By framing depression as a biological error to be corrected, the industry created a simple narrative that bypassed the complexities of the human condition. This medicalization shifted the burden of mental health away from social and environmental contexts, such as unemployment, trauma, and loneliness, and onto the internal biology of the individual.

The Hidden Cost of Symptom Suppression

The disease-centered model suggests that antidepressants work by correcting an underlying pathology. In reality, Dr. Moncrieff argues for a drug-centered model: antidepressants are psychoactive substances that alter normal brain chemistry, much like alcohol or other recreational drugs. While they may temporarily suppress intense emotions, they often induce states of emotional numbing and sexual dysfunction.

This creates a feedback loop where the side effects of the medication, such as numbness, libido loss, and dependency, can worsen the very feelings of distress they were meant to treat. Furthermore, the difficulty of withdrawing from these drugs is often underestimated. Patients who attempt to stop medication may experience intense withdrawal symptoms, which are frequently misidentified by clinicians as a relapse into depression, leading to unnecessary long-term prescriptions.

Why the System Resists Change

The current mental health infrastructure is optimized for chronic treatment. Whether it is the proliferation of ketamine clinics or the reliance on SSRIs, the financial incentives favor long-term annuity models over one-time interventions.

"The problem is, that model isn't great for people who want to sell psychedelics or psychedelic experiences because it's just once or twice that you're going to take the things and if you're setting up a psychedelic clinic... you wanted people to keep coming back. You wanted an annuity."

-- Dr. Joanna Moncrieff

This creates a competitive disadvantage for approaches that prioritize root-cause resolution, such as nutritional optimization, sleep hygiene, and social connection, because these methods empower the patient to recover without requiring ongoing corporate intervention. The system responds by labeling these as alternative or lifestyle factors, effectively sidelining them in favor of more profitable, though less effective, pharmacological solutions.

Key Action Items

• Audit Your Current Narrative: Recognize that a diagnosis of chemical imbalance is a model, not a biological certainty. Over the next quarter, shift your focus toward identifying specific environmental or life stressors contributing to your state.
• Prioritize Foundational Health: Invest in the biological basics, such as cardiovascular exercise, whole-food nutrition, and circadian rhythm regulation. These interventions address systemic inflammation and support mental well-being without the side effects of psychoactive drugs.
• Approach Deprescribing with Caution: If you are considering stopping antidepressants, do not do so abruptly. Work with a sympathetic healthcare provider to create a slow, sensitive tapering plan. This is a long-term investment of 12 to 18 months that requires patience to avoid severe withdrawal.
• Demand Informed Consent: When discussing medication with a provider, ask specifically about the drug-centered effects. Understand that you are taking a substance that alters normal brain function, and weigh that risk against the potential for temporary symptom suppression.
• Cultivate Personal Agency: Recognize that the feeling of helplessness is often a consequence of modern social fragmentation. Seek community and social connection as a primary intervention rather than a secondary one. This pays off in lasting resilience.